The "Global Multiple Sclerosis Drugs Market 2020-2027" report has been added to ResearchAndMarkets.com's offering.
The global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs.
The report is based on a comprehensive research of the entire global multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications.
Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year because 2020 is not appropriate for research base due to the outbreak of COVID-19.
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter's Five Forces
Key Players:
- Abbvie, Inc.
- Acorda Therapeutics Inc.
- Bayer AG
- Biogen Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Merck KgaA
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Teva Pharmaceutical Industries Ltd.
Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
Immunomodulators
- Copaxone
- Avonex/Plegridy
- Gilneya
- Tysabri
- Betaseron/Extavia
- Tecifidera
- Rebif
- Ampyra
- Other Immunomodulators
Immunosuppressants
- Aubagio
- Lemtrada
- Ocrelizumab
- Zinbryta
- Other Immunosuppressants
Based on Drug Class, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
- Monoclonal Antibodies
- Interferon Beta
- Sphingosine 1 Phosphate Receptor Modulators
- Mixed Polymers
- NF-?B Inhibitor
- Pyrimidine Synthesis Inhibitor
- Corticosteroids
- Adrenocorticotropic Hormone
- Other Drug Classes
Based on Drug Category, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
- Large-molecule Drugs
- Small-molecule Drugs
Based on Route of Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
- Oral Administration
- Parenteral Administration
Based on MS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
- Relapsing-remitting MS (RRMS)
- Primary-progressive MS (PPMS)
- Secondary-progressive MS (SPMS)
- Progressive-relapsing MS (PRMS)
Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Geographically, the following regions together with the listed national/local markets are fully investigated:
- North America (U.S., Canada, and Mexico)
- Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
- APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
- South America (Brazil, Chile, Argentina, Rest of South America)
- MEA (UAE, Saudi Arabia, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included.
For more information about this report visit https://www.researchandmarkets.com/r/xgk2bh
View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005451/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
